Latest News
Tuesday March 18, 2008 — AstraZeneca
WILMINGTON, Del., March 18 /PRNewswire-FirstCall/ -- Data from a new study demonstrated that the combination asthma maintenance therapy, SYMBICORT(R) (budesonide/formoterol fumarate dihydrate), provided greater and faster bronchodilatory effects, or opening of the airways, compared with Advair (f...
Monday March 17, 2008 — AstraZeneca
WILMINGTON, Del., March 17 /PRNewswire-FirstCall/ -- A new study analyzed long-term use of the maintenance combination asthma therapy, SYMBICORT(R) (budesonide/formoterol fumarate dihydrate), in treating persistent asthma in children 6 to 11 years old. The study examined the safety of SYMBICORT i...
Wednesday March 12, 2008 — AstraZeneca
WILMINGTON, Del., March 12 /PRNewswire-FirstCall/ -- AstraZeneca announced today that it has completed patient enrollment in two pivotal Phase III studies for vandetanib, the company's investigational, once-daily oral anti-cancer drug, for the second-line treatment of non-small cell lung cancer ...
Friday February 29, 2008 — AstraZeneca
WILMINGTON, Del., Feb. 29 /PRNewswire-FirstCall/ -- AstraZeneca today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for once- daily SEROQUEL XR(TM) (quetiapine fumarate) Extended-Release Tablets to seek approval for the trea...
Friday February 29, 2008 — AstraZeneca
WILMINGTON, Del., Feb. 28 /PRNewswire/ -- AstraZeneca announced today that the U.S. Food and Drug Administration (FDA) has approved the use of NEXIUM(R) (esomeprazole magnesium) in children ages 1 to 11 years old for the short-term treatment of gastroesophageal reflux disease (GERD) for up to 8 ...
Thursday February 28, 2008 — AstraZeneca
WILMINGTON, Del., Feb. 28 /PRNewswire-FirstCall/ -- AstraZeneca announced today that the U.S. Food and Drug Administration (FDA) has approved the use of NEXIUM(R) (esomeprazole magnesium) in children ages 1 to 11 years old for the short-term treatment of gastroesophageal reflux disease (GERD) fo...
Thursday February 28, 2008 — MedImmune
GAITHERSBURG, Md, Feb. 27 /PRNewswire/ -- MedImmune, the manufacturer of FluMist(R) (Influenza Virus Vaccine Live, Intranasal), today lauded the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) for its unanimous vote to expand recommendat...
Friday February 22, 2008 — AstraZeneca
WILMINGTON, Del., Feb. 21 /PRNewswire-FirstCall/ -- AstraZeneca believes this lawsuit is legally and factually unfounded and we intend to appeal to the Alabama Supreme Court, if the trial court does not reject the jury's verdict. The case was based on the misleading premise that the Alabama State...
Wednesday February 20, 2008 — MedImmune
GAITHERSBURG, Md., Feb. 19 /PRNewswire-FirstCall/ -- A recent survey of 202 neonatologists and pediatricians, which examined current attitudes and practices when caring for the specialized health needs of preterm infants, revealed that most respondents (70 percent) feel the United States' healthc...
Friday February 8, 2008 — MedImmune
GAITHERSBURG, Md., Feb. 7 /PRNewswire/ -- MedImmune today announced that it has strengthened its leadership in research, human resources (HR) and regulatory affairs with three key promotions and has also hired a new head of vaccine manufacturing. Peter A. Kiener, D. Phil. has been appointed to ex...
Tuesday February 5, 2008 — Zacks.com: Analyst Blog
AstraZeneca PLC (AZN) is engaged in the research, development, manufacturing and marketing of ethical (prescription) pharmaceutical products. The company ranks among the top pharmaceutical companies in the world based on revenues and global sales force. It is a leader in cardiovascular, c...
Tuesday February 5, 2008 — MedImmune
GAITHERSBURG, Md., Feb. 4 /PRNewswire/ -- MedImmune announced today it submitted to the U.S. Food Drug Administration (FDA) on January 30 a Biologics License Application (BLA) for motavizumab, an investigational monoclonal antibody (MAb) derived from recombinant DNA technology. The motavizumab B...
Thursday January 24, 2008 — AstraZeneca
HOUSTON and WILMINGTON, Del., Jan. 24 /PRNewswire-FirstCall/ -- The University of Texas M. D. Anderson Cancer Center and AstraZeneca today announced that they will collaborate to help advance understanding of neuropathic pain caused by cancer chemotherapy, a side effect that often limits optimal...
Wednesday January 23, 2008 — AstraZeneca
WILMINGTON, Del., Jan. 22 /PRNewswire-FirstCall/ -- AstraZeneca has been named to FORTUNE magazine's list of the "100 Best Companies to Work For" list for the third time since 2004. The company is ranked 83rd overall and was specifically cited for its on-site wellness programs, fitness center an...
Thursday January 17, 2008 — Seven Summits Investment Research
CHICAGO, Jan. 16 /PRNewswire/ -- Seven Summits Research releases NewsBites on key stocks.Seven Summits Strategic Investments NewsBites are available to all investors at:http://www.go7now.com/nb/0116Y (Note: You may have to copy this link into your browser then press the [ENTER] key.)Today's Seven...
Tuesday January 8, 2008 — MedImmune
GAITHERSBURG, Md., Jan. 7 /PRNewswire/ -- MedImmune, the operationally independent worldwide biologics unit of AstraZeneca plc , today announced that its highly successful venture capital fund, MedImmune Ventures, will broaden its focus to include areas of strategic interest to both organizations...
Sunday January 6, 2008 — StockWeb
Dividend stocks shouldn't miss in your portfolio for 2008. If you run stock screening for large cap (over $5 bil. market cap) with low P/Evaluation you get mostly financial companies. Dividend yields are tempting but I'd stay away. Those are with high probability for dividend payment cuts. Other s...
Wednesday January 2, 2008 — AstraZeneca
WILMINGTON, Del., Jan. 2 /PRNewswire-FirstCall/ -- AstraZeneca today announced that the company has submitted two separate supplemental New Drug Applications (sNDAs) to the U.S. Food and Drug Administration (FDA) for once-daily SEROQUEL XR(TM) (quetiapine fumarate) Extended-Release Tablets to se...
Saturday December 29, 2007 — Zacks.com: Analyst Blog
The following excerpts explain why Zacks senior pharmaceutical industry analyst Brian Marckx, CFA expresses a neutral viewpoint on AstraZeneca PLC (AZN), the pharma giant:'AstraZeneca PLC is engaged in the research, development, manufacturing and marketing of ethical (prescription) pharma...
Tuesday June 5, 2007 — Zacks.com: Analyst Blog
Zacks senior drug industry analyst Jason Napodano, CFA has reiterated his Hold recommendation on AstraZeneca (AZN) shares this morning. We looked into the report to find the details:
AstraZeneca PLC is engaged in the research, development, manufacturing and marketing of ethical (pre...